Perrigo reported Q4 FY2025 net sales of USD 1.11 billion (-2.5%) and FY2025 net sales of USD 4.25 billion (-2.8%). Q4 FY2025 GAAP diluted EPS from continuing operations was USD -10.20, reflecting a USD 1.3 billion goodwill impairment charge recorded as of December 31, 2025; Q4 adjusted diluted EPS was USD 0.77. For FY2025, GAAP diluted EPS from continuing operations was USD -10.12, while adjusted diluted EPS was USD 2.75 (+7.0%). In Q4, adjusted gross margin was 36.1% and adjusted operating margin was 15.1%; for FY2025, adjusted gross margin was 38.7% and adjusted operating margin was 14.6%. FY2025 YTD operating cash flow was USD 239 million, with cash and cash equivalents of USD 532 million and total debt of USD 3.64 billion at December 31, 2025. Perrigo said it advanced its “3-S Plan,” and noted store brand OTC and key brands gained share in 2025 despite soft category consumption. The company launched a new two-year operational enhancement program targeting USD 80 million to USD 100 million in pre-tax annualized savings by the end of FY2027 (with a planned workforce reduction of about 7%), and said it will transition to new reporting segments starting Q1 2026. Perrigo also reiterated it expects to close the divestiture of its Dermacosmetics branded business in Q2 2026, and said it is issuing FY2026 “All In” adjusted diluted EPS guidance of USD 2.00 to USD 2.30 and net sales growth guidance of -5.5% to -1.5%.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Perrigo Company plc published the original content used to generate this news brief via PR Newswire (Ref. ID: DE96330) on February 26, 2026, and is solely responsible for the information contained therein.
Comments